The developmental research program is a special feature of the SPORE grant which allows sponsored institutions to fund important new pilot projects with promising translational potential, but would have difficulty in providing sufficient preliminary data for an independently funded NIH grant. This is a crucial part of our SPORE program as it provides a pipeline and testing ground for novel substrates for translational impact. These projects are intended to last one year with the possibility of a second year of support with the demonstration of sufficient progress and are budgeted with the intention of that the majority of the funds be spent on supplies, rather than salary support. Pilot projects which make significant progress and are deemed to be capable of high translational impact will be considered for promotion to full SPORE projects. To be eligible, the applicant must have a current academic appointment at any of the Johns Hopkins Medical Institutions, Howard University or University of Maryland. Applicants must hold an M.D., or Ph.D. degree or both. The applicants are expected to provide evidence of a significant research commitment (at least 15% effort commitment) to ensure that the proposal can in fact be addressed in an effective and productive way. As many as 10 developmental research projects will be funded annually, two by funds budgeted within the SPORE, and the remainder through funds available through The Patrick C. Walsh Prostate Cancer Research Fund. The Developmental Research Program will be maintained throughout the grant period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058236-15
Application #
7919413
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
15
Fiscal Year
2009
Total Cost
$150,997
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Karnes, R Jeffrey; Choeurng, Voleak; Ross, Ashley E et al. (2018) Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol 73:168-175
Menezes, Mitchell E; Bhoopathi, Praveen; Pradhan, Anjan K et al. (2018) Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases. Adv Cancer Res 138:143-182
Jiang, Wen; Ulmert, David; Simons, Brian W et al. (2018) The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates. Nucl Med Biol 62-63:1-8
Tsang, Sabrina H; Peisch, Samuel F; Rowan, Brendan et al. (2018) Association between Trichomonas vaginalis and prostate cancer mortality. Int J Cancer :
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Kaur, Harsimar B; Guedes, Liana B; Lu, Jiayun et al. (2018) Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Mod Pathol 31:1539-1552
Zhu, Yezi; Sharp, Adam; Anderson, Courtney M et al. (2018) Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol 73:727-735
Teply, Benjamin A; Wang, Hao; Luber, Brandon et al. (2018) Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol 19:76-86
Zennami, Kenji; Choi, Su Mi; Liao, Ross et al. (2018) PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance. Mol Cancer Res :

Showing the most recent 10 out of 750 publications